BRPI1014368A2 - formulação lipídica de promotor da apoptose - Google Patents

formulação lipídica de promotor da apoptose

Info

Publication number
BRPI1014368A2
BRPI1014368A2 BRPI1014368A BRPI1014368A BRPI1014368A2 BR PI1014368 A2 BRPI1014368 A2 BR PI1014368A2 BR PI1014368 A BRPI1014368 A BR PI1014368A BR PI1014368 A BRPI1014368 A BR PI1014368A BR PI1014368 A2 BRPI1014368 A2 BR PI1014368A2
Authority
BR
Brazil
Prior art keywords
lipid formulation
apoptosis promoter
apoptosis
promoter
lipid
Prior art date
Application number
BRPI1014368A
Other languages
English (en)
Inventor
Anthony R Haight
Cristian Fischer
Deliang Zhou
Eric Schmitt
Katherine Heemstra
Kennan Marsh
Michael Fickes
Paul David
Peter Mayer
Ping Tong
Vitaly Rubin
Yeshiwant Sanzgirl
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI1014368A2 publication Critical patent/BRPI1014368A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1014368A 2009-04-30 2010-04-30 formulação lipídica de promotor da apoptose BRPI1014368A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17424509P 2009-04-30 2009-04-30
PCT/US2010/033074 WO2010127192A1 (en) 2009-04-30 2010-04-30 Lipid formulation of apoptosis promoter

Publications (1)

Publication Number Publication Date
BRPI1014368A2 true BRPI1014368A2 (pt) 2016-04-05

Family

ID=42732500

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014368A BRPI1014368A2 (pt) 2009-04-30 2010-04-30 formulação lipídica de promotor da apoptose

Country Status (17)

Country Link
US (1) US20100280031A1 (pt)
EP (1) EP2424500A1 (pt)
JP (1) JP2012525434A (pt)
KR (1) KR20120013416A (pt)
CN (1) CN102458361A (pt)
AR (1) AR076512A1 (pt)
AU (1) AU2010242925A1 (pt)
BR (1) BRPI1014368A2 (pt)
CA (1) CA2758534A1 (pt)
IL (1) IL215473A0 (pt)
MX (1) MX2011011526A (pt)
RU (1) RU2011148518A (pt)
SG (1) SG175147A1 (pt)
TW (1) TW201043605A (pt)
UY (1) UY32600A (pt)
WO (1) WO2010127192A1 (pt)
ZA (1) ZA201107593B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
MX360638B (es) 2011-04-28 2018-11-12 Univ Texas Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
CN102836160A (zh) * 2012-10-10 2012-12-26 武汉大学 一种治疗癌症的组合药物
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
IL156460A0 (en) * 2001-01-31 2004-01-04 Pfizer Prod Inc Ether derivatives useful as inhibitors of pde4 isozymes
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
CA2606147C (en) * 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
US20090149461A1 (en) * 2007-12-06 2009-06-11 Abbott Laboratories Method of treating cancer
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
WO2010147899A1 (en) * 2009-06-18 2010-12-23 Abbott Laboratories Stable nanoparticulate drug suspension
US8362014B2 (en) * 2009-09-20 2013-01-29 Abbvie Inc. ABT-263 crystalline forms

Also Published As

Publication number Publication date
MX2011011526A (es) 2011-11-18
CA2758534A1 (en) 2010-11-04
UY32600A (es) 2010-12-31
ZA201107593B (en) 2012-06-27
TW201043605A (en) 2010-12-16
WO2010127192A1 (en) 2010-11-04
KR20120013416A (ko) 2012-02-14
JP2012525434A (ja) 2012-10-22
SG175147A1 (en) 2011-11-28
AU2010242925A1 (en) 2011-11-10
AR076512A1 (es) 2011-06-15
EP2424500A1 (en) 2012-03-07
CN102458361A (zh) 2012-05-16
IL215473A0 (en) 2011-12-29
US20100280031A1 (en) 2010-11-04
RU2011148518A (ru) 2013-06-10

Similar Documents

Publication Publication Date Title
LTC2498758I2 (lt) Dvisluoksnės tabletės formuluotės
DK3431076T3 (da) Forbedret lipidformulering
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
BRPI1014492A2 (pt) formação lípida estabilizada de promotor de apoptose
EP2454554A4 (en) SAME PATH Interferometer
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
BRPI1012959A2 (pt) dispersoes solidas contendo um agente promotor de apoptose
EP2420244A4 (en) MEANS TO PROMOTE FATTY CHANGE
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI1014368A2 (pt) formulação lipídica de promotor da apoptose
DK2496493T3 (da) Støtteenhed
PL2358571T3 (pl) Stopa podporowa
UA20209S (uk) Крісло гіпертермотерапевтичне
SE0900379L (sv) Benstöd
IT1393323B1 (it) Orologio da polso
FI20095347A0 (fi) Kaksoislaserlaitteisto
TH106983B (th) อนุพันธ์ของซับสทิทิวเทด พิริมิโด ไอโซควิโนลีน
TH97629B (th) เก้าอี้
TH103028B (th) ผลิตภัณฑ์ซึมซับ
TH105267B (th) ผลิตภัณฑ์ซึมซับ
TH102496B (th) ผลิตภัณฑ์ซึมซับ
TH102473B (th) ผลิตภัณฑ์ซึมซับ
TH102068B (th) ผลิตภัณฑ์ซึมซับ
TH102067B (th) ผลิตภัณฑ์ซึมซับ
TH108912B (th) ผลิตภัณฑ์ซึมซับ

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.